Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Cells in SLE
NCT06900764Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Nov 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-CD1a CAR-T cells in systemic lupus erythematosus (SLE). Primary endpoints: Dose Limiting Toxicity at 28 days and Frequency of Adverse Events and Serious Adverse Events at 24 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
anti-CD1a CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06900764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900764.